FR2686087B1 - - Google Patents
Info
- Publication number
- FR2686087B1 FR2686087B1 FR9200255A FR9200255A FR2686087B1 FR 2686087 B1 FR2686087 B1 FR 2686087B1 FR 9200255 A FR9200255 A FR 9200255A FR 9200255 A FR9200255 A FR 9200255A FR 2686087 B1 FR2686087 B1 FR 2686087B1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9200255A FR2686087A1 (fr) | 1992-01-13 | 1992-01-13 | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| PCT/FR1993/000025 WO1993014125A1 (fr) | 1992-01-13 | 1993-01-13 | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9200255A FR2686087A1 (fr) | 1992-01-13 | 1992-01-13 | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2686087A1 FR2686087A1 (fr) | 1993-07-16 |
| FR2686087B1 true FR2686087B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1994-04-22 |
Family
ID=9425559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9200255A Granted FR2686087A1 (fr) | 1992-01-13 | 1992-01-13 | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2686087A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
| WO (1) | WO1993014125A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| ATE494306T1 (de) | 2007-02-14 | 2011-01-15 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| EP2222707B1 (en) | 2007-11-21 | 2016-01-06 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| NZ593964A (en) | 2008-12-19 | 2012-12-21 | Univ Zuerich | Human anti-alpha-synuclein autoantibodies |
| US8496938B2 (en) | 2009-05-08 | 2013-07-30 | Vaccinex, Inc. | Anti-CD100 neutralizing neutralizing antibodies and methods of using the same |
| EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| TR201815563T4 (tr) | 2011-06-23 | 2018-11-21 | Biogen Int Neuroscience Gmbh | Anti-alfa sinüklein bağlayıcı moleküller. |
| ES2669209T3 (es) | 2011-10-11 | 2018-05-24 | Vaccinex, Inc. | Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica |
| JP6263473B2 (ja) | 2011-11-02 | 2018-01-31 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| EP2820045B1 (en) | 2012-03-02 | 2018-08-22 | Vaccinex, Inc. | Methods for the treatment of b cell-mediated inflammatory diseases |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| EP2951204B1 (en) | 2013-01-31 | 2019-05-22 | Vaccinex, Inc. | Methods for increasing immunoglobulin a levels |
| US20160002325A1 (en) | 2013-03-08 | 2016-01-07 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
| PL3013350T3 (pl) | 2013-06-25 | 2020-06-15 | Vaccinex, Inc. | Zastosowanie cząsteczek hamujących semaforynę-4d w kombinacji z terapią modulującą odporność w celu hamowania wzrostu i przerzutów guza |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| ES2886114T3 (es) | 2015-03-31 | 2021-12-16 | Medimmune Ltd | Una nueva forma de IL33, formas mutadas de IL33, anticuerpos, ensayos y métodos para usar los mismos |
| AU2017354743A1 (en) | 2016-11-07 | 2019-06-06 | DegenRx B.V | Novel amyloid beta oligomer specific binding molecule |
| BR112019019597A2 (pt) | 2017-03-20 | 2020-04-14 | Vaccinex Inc | tratamento de câncer com um anticorpo anti-semaforina- 4d em combinação com um agente de modulação epigenética |
| AU2018261947B2 (en) | 2017-05-05 | 2024-06-13 | Vaccinex, Inc. | Human anti-semaphorin 4D antibody |
| CN118370815A (zh) | 2017-08-22 | 2024-07-23 | 渤健马萨诸塞州股份有限公司 | 含有抗β淀粉样蛋白抗体的药物组合物 |
| AU2020244862B2 (en) | 2019-03-28 | 2023-01-05 | Merck Kgaa | Semaphorin-4D antagonists for use in cancer therapy |
| US11660330B2 (en) | 2019-06-21 | 2023-05-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy |
| US20210032322A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor |
| EP4172205A1 (en) | 2020-06-25 | 2023-05-03 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for the treatment of rett syndrome |
| AU2021465518A1 (en) | 2021-09-27 | 2024-05-02 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| WO2023154906A1 (en) | 2022-02-13 | 2023-08-17 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3942579A1 (de) * | 1989-12-22 | 1991-06-27 | Basf Ag | Neue proteine |
-
1992
- 1992-01-13 FR FR9200255A patent/FR2686087A1/fr active Granted
-
1993
- 1993-01-13 WO PCT/FR1993/000025 patent/WO1993014125A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO1993014125A1 (fr) | 1993-07-22 |
| FR2686087A1 (fr) | 1993-07-16 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |